No data to show
XBRU
SEQUA
Market cap60mUSD
May 22, Last price
0.98EUR
1D
-3.92%
1Q
-38.36%
IPO
-86.86%
Name
Sequana Medical NV
Chart & Performance
P/E
—
P/S
75.23
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.41%
Rev. gr., 5y
-7.10%
Revenues
712k
-22.82%
Net income
-33m
L+5.85%
CFO
-29m
L+5.75%
Earnings
May 23, 2025
Profile
Sequana Medical NV, a commercial stage medical device company, engages in the development of platform for the treatment of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; Direct Sodium Removal (DSR) for the treatment of persistent congestion due to heart failure; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with fluid overload due to heart failure. It operates in Belgium, Germany, France, Switzerland, and internationally. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 712 -22.82% | 923 149.04% | |||||||
Cost of revenue | 12,947 | 16,839 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (12,235) | (15,916) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 466 | 387 | |||||||
Tax Rate | |||||||||
NOPAT | (12,701) | (16,303) | |||||||
Net income | (32,564) 5.85% | (30,763) 30.27% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 15,786 | 28,420 | |||||||
BB yield | -14.74% | -20.80% | |||||||
| Debt | |||||||||
Debt current | 8,087 | 4,790 | |||||||
Long-term debt | 10,166 | 13,719 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 668 | 228 | |||||||
Net debt | 15,568 | (452) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (29,063) | (27,482) | |||||||
CAPEX | (711) | (677) | |||||||
Cash from investing activities | (721) | (653) | |||||||
Cash from financing activities | 13,461 | 37,324 | |||||||
FCF | (7,867) | (17,102) | |||||||
| Balance | |||||||||
Cash | 2,584 | 18,875 | |||||||
Long term investments | 100 | 86 | |||||||
Excess cash | 2,649 | 18,915 | |||||||
Stockholders' equity | (205,110) | (170,998) | |||||||
Invested Capital | 203,832 | 186,665 | |||||||
ROIC | |||||||||
ROCE | 957.66% | ||||||||
| EV | |||||||||
Common stock shares outstanding | 26,774 | 22,770 | |||||||
Price | 4.00 -33.33% | 6.00 -20.63% | |||||||
Market cap | 107,096 -21.61% | 136,617 -0.78% | |||||||
EV | 122,665 | 137,645 | |||||||
EBITDA | (11,574) | (15,605) | |||||||
EV/EBITDA | |||||||||
Interest | 4,288 | 880 | |||||||
Interest/NOPBT | |||||||||